Company research / CHRS
Coherus Oncology, Inc. (CHRS)
- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
For the year ended 2025-12-31, Coherus Oncology, Inc. reported revenue of $42.17M. Revenue grew 59.8% from the prior annual period.
Key ratios (year ended 2025-12-31)
-429.5%
Operating margin
398.4%
Net margin
275.4%
Return on year-end equity
59.8%
Revenue growth (YoY)
Beyond the statements
Follow the company.
Explore new filings, reported insider transactions and company relationships.